Last reviewed · How we verify
THR-100
THR-100 is a recombinant human monoclonal antibody that targets the SARS-CoV-2 spike protein.
THR-100 is a recombinant human monoclonal antibody that targets the SARS-CoV-2 spike protein. Used for Prevention of COVID-19 disease.
At a glance
| Generic name | THR-100 |
|---|---|
| Also known as | Staphylokinase |
| Sponsor | Bharat Biotech International Limited |
| Drug class | COVID-19 vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the spike protein, thereby preventing the virus from entering host cells. This mechanism of action is similar to other COVID-19 vaccines.
Approved indications
- Prevention of COVID-19 disease
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THR-100 CI brief — competitive landscape report
- THR-100 updates RSS · CI watch RSS
- Bharat Biotech International Limited portfolio CI